Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024

Press Release // April 22, 2024
 

Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024
 

Munich - Formycon AG (FWB: FYB, 'Formycon') today announced details of the conference call to release the results of the financial year 2023 on April 25, 2024. The management board will discuss the company's developments and key financial figures and will provide an outlook for the year 2024. The conference call, which will be broadcasted live on the internet, will take place on April 25, 2024, at 3:00 PM (CEST) in English.

To register for participation, please sign up at:
https://research-hub.de/events/registration/2024-04-25-15-00/FYB-GR

Here you can participate in the event via your web browser or the Zoom app.

For participation via telephone, a list of international phone numbers is available.
You can find an overview at the following link: https://zoom.us/u/aJj3tcDoQ

To join the earnings call via telephone, please use the webinar ID: 962 8767 3566

Following a short presentation, the Executive Board will be available to answer analysts’  questions. A recording of the conference call can subsequently be accessed via the Formycon website at: https://www.formycon.com/en/investor-relations/facts-figures/

Formycon in dialogue

In addition, representatives of the Executive Board will participate in the following international investor conferences in the coming weeks:
 

• April 23, 2024
  Metzler Small Cap Days
  Enno Spillner (CFO)
  Frankfurt
   
• April 30, 2024
  Jefferies Fireside Chat
  Dr. Stefan Glombitza (CEO), Enno Spillner (CFO)
  Virtual
   
• May 13 – 15, 2024
  Equity Forum Spring Conference 2024
  Dr. Stefan Glombitza (CEO)
  Frankfurt
   
• May 15 – 17, 2024
  Hauck Aufhäuser Stockpicker Summit
  Enno Spillner (CFO)
  Kitzbühel
   
• May 21 – 23, 2024
  Berenberg European Conference
  Enno Spillner (CFO)
  New York City
   
• June 3, 2024
  mwb Research Roundtable
  Dr. Stefan Glombitza (CEO), Enno Spillner (CFO), Nicola Mikulcik (CBO), Dr. Andreas Seidl (CSO)
  Virtual
   
• June 5 – 6, 2024
  Jefferies Global Healthcare Conference NYC
  Enno Spillner (CFO)
  New York City
   
• June 6 – 7, 2024
  Warburg Highlights
  Dr. Stefan Glombitza (CEO)
  Hamburg
   

Please find our current Events at:
https://www.formycon.com/en/investor-relations/calendar/

About Formycon:
Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/Ranibizumab, Formycon already has a biosimilar on the market in Europe and the USA. Another five biosimilar candidates are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines. Formycon AG is headquartered in Munich and is listed on the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY. Further information can be found at: https://www.formycon.com/

About Biosimilars:
Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare providers. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.

Contact:
Sabrina Müller,
Director Investor Relations & Corporate Communications,
Formycon AG
Fraunhoferstr. 15
82152 Planegg-Martinsried
Germany

Tel.: +49 (0) 89 - 86 46 67 149
Fax: + 49 (0) 89 - 86 46 67 110
Sabrina.Mueller@formycon.com

Disclaimer:
This press release may contain forward-looking statements and information which are based on Formycon’s current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.